MDM2 (phospho-Ser260) Antibody
- Known as:
- MDM2 (phosphorilated-Ser260) Antibody
- Catalog number:
- abx000147
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- MDM2 (phospho-Ser260) Antibody
Related genes to: MDM2 (phospho-Ser260) Antibody
- Gene:
- MDM2 NIH gene
- Name:
- MDM2 proto-oncogene
- Previous symbol:
- -
- Synonyms:
- HDM2, MGC5370
- Chromosome:
- 12q15
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-10
- Date modifiied:
- 2017-12-01
Related products to: MDM2 (phospho-Ser260) Antibody
Related articles to: MDM2 (phospho-Ser260) Antibody
- Primary cardiac intimal sarcoma is an exceptionally rare and aggressive malignancy, representing a small subset of primary cardiac tumors. Owing to its rapid progression and limited treatment options, the median survival is typically less than 1 year. We report a rare case of primary cardiac intimal sarcoma with MDM2 amplification, in which the patient achieved survival exceeding 1 year through a multimodal treatment approach, offering valuable insights into the management of this highly lethal disease. - Source: PubMed
Publication date: 2025/09/26
Zhong ShishiLuo YanhongFei YunxiaZhang Siyu - The study aim was to apply murine double minute 2 (MDM2)-siRNA to a biodegradable siRNA delivery vector, ternary complex, for treating colorectal cancer peritoneal dissemination. The ternary complex containing MDM2-siRNA (MDM2-siRNA complex) was constructed by mixing MDM2-siRNA, dendrigraft poly-L-lysine, and γ-polyglutamic acid. Cellular uptake of the ternary complex and suppressive effect on MDM2-mRNA were determined in a mouse colorectal cancer cell line. Tumor-growth inhibition by the MDM2-siRNA complex was evaluated in peritoneal dissemination model mice. The MDM2-siRNA complex, with an approximately 177 nm particle size and -35 mV ζ-potential, prevented degradation of the inner siRNA by RNase. In the in vitro study, the ternary complex was highly taken up by the cells, and 2 μg/mL of the MDM2-siRNA complex significantly decreased MDM2-mRNA to about 30% of control cells. Intraperitoneal administration in colorectal cancer peritoneal dissemination model mice showed little effect of the ternary complex containing scramble-siRNA on cancer growth in the peritoneal cavity. Conversely, the MDM2-siRNA complex significantly reduced peritoneal dissemination to less than 1/1000th of control mice and successfully prolonged survival time. In this study, we found that the biodegradable MDM2-siRNA complex had a suppressive effect on MDM2-mRNA in cancer cells and tumor growth of peritoneal dissemination. - Source: PubMed
Publication date: 2025/09/12
Kurosaki TomoakiOkada AkariTakashima YuukiSasaki HitoshiKodama Yukinobu - Medulloblastoma (MB) is the most common childhood brain tumor arising from the cerebellum. PI3K and BRD4 signaling pathways are known to induce MB cell growth, cancer stem cell (CSC) proliferation, and tumor resistance. Further, the tumor suppressor gene TP53 is found to be inactivated in MB due to overexpression of its negative regulator MDM2. In this study, we synthesized MDP5, a potent BRD4/PI3K dual inhibitor, and JW475A, a potent dual MDM2 and XIAP inhibitor. The combination of these two drugs significantly decreased the colony formation capacity compared to individual drugs. Given the challenge of inefficient drug transport across the blood-brain barrier (BBB), we prepared rabies virus glycoprotein (RVG) peptide decorated lipid nanoparticles (LNPs), which showed 4.9 ± 0.1 and 4.8 ± 0.1 % loading for MDP5 and JW475A, respectively. In vivo studies in mice showed that Cy5.5 labeled RVG-LNPs were detected in the brain after systemic administration. Combination drug-loaded RVG-LNPs significantly decreased the MB growth in orthotopic mouse model of MB compared to free drug combination and non-targeted LNPs. This study indicates that MDP5 and JW475A -loaded RVG-LNPs are a promising drug brain delivery system worth exploring further in clinical settings for MB therapy. - Source: PubMed
Publication date: 2025/09/24
Sethi BhartiGupta AdityaPan QiaoyuMahto SohanChittipolu AjaykumarErickson HelenKumar VirenderChen YanfeiWu ZhongzhiDong YuxiangLi WeiRonning Donald RCoulter Donald WMahato Ram I - This study aimed to establish orthotopic intracranial patient-derived xenograft (PDX) models to investigate molecular and pathological features and to evaluate potential preclinical therapeutic approaches in glioblastoma (GBM). - Source: PubMed
Publication date: 2025/09/25
Tran Thi-Anh-ThuyAn SinaeLim JunghyunKim Young-HeeShim AhyeonHan TaewooKim HawsanPark Sue-JeeKim Yeong JinMoon Kyung-SubKim In-YoungJung ShinLee Chul WonLee Kyung-HwaPark Ae KyungJung Tae-Young - Patients with non-small cell lung cancer (NSCLC) harboring exon 14 skipping mutations (ex14) or amplifications (amp) have demonstrated varied responses to immunotherapy. This study aimed to better understand the genomic and immune characteristics of altered NSCLC. - Source: PubMed
Publication date: 2025/09/26
Liu ManluMinne Rachel LJaveri SaahilJohnson D BryanTomlins Scott AKimple Randall JBaschnagel Andrew M